These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 39380185)
1. A combination of lymphatic drug delivery of anti-CTLA-4 antibody and local radiotherapy for solid-tumor treatment. Takagi K; Sukhbaatar A; Inaba Y; Mori S; Kodama T Cancer Sci; 2024 Oct; ():. PubMed ID: 39380185 [TBL] [Abstract][Full Text] [Related]
2. Combination therapy of lymphatic drug delivery and total body irradiation in a metastatic lymph node and lung mouse model. Sora S; Sukhbaatar A; Fukushige S; Mori S; Sakamoto M; Kodama T Cancer Sci; 2023 Jan; 114(1):227-235. PubMed ID: 36056924 [TBL] [Abstract][Full Text] [Related]
4. Docetaxel administered through a novel lymphatic drug delivery system (LDDS) improved treatment outcomes for lymph node metastasis. Sukhbaatar A; Mori S; Sugiura T; Kodama T Biomed Pharmacother; 2024 Feb; 171():116085. PubMed ID: 38171241 [TBL] [Abstract][Full Text] [Related]
5. Metastatic lymph node targeted CTLA4 blockade: a potent intervention for local and distant metastases with minimal ICI-induced pneumonia. Mishra R; Sukhbaatar A; Mori S; Kodama T J Exp Clin Cancer Res; 2023 Jun; 42(1):132. PubMed ID: 37259163 [TBL] [Abstract][Full Text] [Related]
6. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. van Hooren L; Sandin LC; Moskalev I; Ellmark P; Dimberg A; Black P; Tötterman TH; Mangsbo SM Eur J Immunol; 2017 Feb; 47(2):385-393. PubMed ID: 27873300 [TBL] [Abstract][Full Text] [Related]
7. Treatment of false-negative metastatic lymph nodes by a lymphatic drug delivery system with 5-fluorouracil. Fujii H; Horie S; Sukhbaatar A; Mishra R; Sakamoto M; Mori S; Kodama T Cancer Med; 2019 May; 8(5):2241-2251. PubMed ID: 30945479 [TBL] [Abstract][Full Text] [Related]
8. Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. Yoshimoto Y; Suzuki Y; Mimura K; Ando K; Oike T; Sato H; Okonogi N; Maruyama T; Izawa S; Noda SE; Fujii H; Kono K; Nakano T PLoS One; 2014; 9(3):e92572. PubMed ID: 24686897 [TBL] [Abstract][Full Text] [Related]
10. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085 [TBL] [Abstract][Full Text] [Related]
11. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Dewan MZ; Galloway AE; Kawashima N; Dewyngaert JK; Babb JS; Formenti SC; Demaria S Clin Cancer Res; 2009 Sep; 15(17):5379-88. PubMed ID: 19706802 [TBL] [Abstract][Full Text] [Related]
12. Intranodal pressure of a metastatic lymph node reflects the response to lymphatic drug delivery system. Kato S; Takeda K; Sukhbaatar A; Sakamoto M; Mori S; Shiga K; Kodama T Cancer Sci; 2020 Nov; 111(11):4232-4241. PubMed ID: 32882076 [TBL] [Abstract][Full Text] [Related]
13. Protocols for the Evaluation of a Lymphatic Drug Delivery System Combined with Bioluminescence to Treat Metastatic Lymph Nodes. Sukhbaatar A; Kodama T Methods Mol Biol; 2022; 2524():333-346. PubMed ID: 35821485 [TBL] [Abstract][Full Text] [Related]
14. Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes. Pilones KA; Aryankalayil J; Babb JS; Demaria S J Immunother Cancer; 2014; 2(1):37. PubMed ID: 25349699 [TBL] [Abstract][Full Text] [Related]
15. Optimization of the delivery of molecules into lymph nodes using a lymphatic drug delivery system with ultrasound. Kato S; Yoshiba S; Mori S; Kodama T Int J Pharm; 2021 Mar; 597():120324. PubMed ID: 33540016 [TBL] [Abstract][Full Text] [Related]
16. Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Pilones KA; Kawashima N; Yang AM; Babb JS; Formenti SC; Demaria S Clin Cancer Res; 2009 Jan; 15(2):597-606. PubMed ID: 19147765 [TBL] [Abstract][Full Text] [Related]
17. Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage Duperret EK; Trautz A; Stoltz R; Patel A; Wise MC; Perales-Puchalt A; Smith T; Broderick KE; Masteller E; Kim JJ; Humeau L; Muthumani K; Weiner DB Cancer Res; 2018 Nov; 78(22):6363-6370. PubMed ID: 30287678 [TBL] [Abstract][Full Text] [Related]
18. Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition. Newton JM; Hanoteau A; Liu HC; Gaspero A; Parikh F; Gartrell-Corrado RD; Hart TD; Laoui D; Van Ginderachter JA; Dharmaraj N; Spanos WC; Saenger Y; Young S; Sikora AG J Immunother Cancer; 2019 Aug; 7(1):216. PubMed ID: 31409394 [TBL] [Abstract][Full Text] [Related]